Ruggero Spoto

Dr. Ruggero Spoto

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2017 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
DADaniela Alterio
Daniela Alterio
MGMarianna Alessandra Gerardi
Marianna Alessandra Gerardi
LCLaura Cella
Laura Cella
RSRuggero Spoto
Ruggero Spoto
VZV. Zurlo
V. Zurlo
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa

6 October 2022 in La radiologia medica
Verified
Journal Article
Open access
PDF file
IMIcro Meattini
Icro Meattini
IPIsabella Palumbo
Isabella Palumbo
CBCarlotta Becherini
Carlotta Becherini
SBSimona Borghesi
Simona Borghesi
FCFrancesca Cucciarelli
Francesca Cucciarelli
LLLorenzo Livi
Lorenzo Livi
Recent advances in non-metastatic breast cancer radiation therapy significantly reshaped our views on modern dose and fractionation schedules. Especially the advent of hypofractionation and partial breast irradiation defined a new concept of treatment optimization, that should strongly include both patient and tumour characteristics in the physician’s decision-making process. Unfortunately, hypofractionation for breast cancer radiation therapy needed long time to enter the routine practice during the last decades despite the level-1 evidence published over time. Hereby we present the Italian Association for Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation to harmonically boost routine clinical practice implementation following evidence-based data.

1 October 2022 in European Journal of Breast Health
Verified
Journal Article
Closed access
Damiano GentileDamiano Gentile
Damiano Gentile
ASAndrea Sagona
Andrea Sagona
RSRuggero Spoto
Ruggero Spoto
DFDavide Franceschini
Davide Franceschini
SVStefano Vaccari
Stefano Vaccari
CTCorrado Tinterri
Corrado Tinterri
Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy would provide better oncological outcomes. The objective of this study was to describe the clinical features of these patients, to compare the two surgical alternatives (salvage mastectomy versus second BCS) in terms of oncological results, and to identify independent factors influencing prognosis and surgical treatment. We retrospectively reviewed all the consecutive patients with histologically confirmed TN or HER2-enriched IBCR. Disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed and compared between the two groups. Eighty-five patients were affected by TN or HER2-enriched IBCR. The majority of patients (72.9%) were treated with salvage mastectomy. There was no significant difference in terms of DFS between patients receiving a second BCS or mastectomy (p = 0.596). However, patients undergoing a second BCS had significantly better DDFS, OS and BCSS compared to mastectomy (p = 0.009; p = 0.002; p = 0.001, respectively). Tumor dimension <16 mm was found to significantly increase the probability of receiving a second BCS and positively affects recurrence and survival outcomes. Salvage mastectomy represents an independent poor prognostic factor for OS and BCSS. Salvage mastectomy is not always necessary and it does not seem to increase survival compared to a second BCS. In patients with small aggressive subtypes of IBCR, a second conservative approach can still be evaluated and offered, presenting acceptable loco-regional control and survival.

17 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
DFDavide Franceschini
Davide Franceschini
TCTiziana Comito
Tiziana Comito
AGAnna Di Gallo
Anna Di Gallo
VVVeronica Vernier
Veronica Vernier
AMAntonio Marco Marzo
Antonio Marco Marzo
MSMarta Scorsetti
Marta Scorsetti
Aims: We report the mature toxicity data of a phase II non-randomized trial on the use of SBRT for lung and liver oligometastases. Methods: Oligometastatic patients from breast cancer were treated with SBRT for up to five lung and/or liver lesions. Inclusion criteria were: age > 18 years, ECOG 0–2, diagnosis of breast cancer, less than five lung/liver lesions (with a maximum diameter <5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. Various dose–fractionation schedules were used. Then, a 4D-CT scan and FDG-CTPET were acquired for simulation and fused for target definition. Results: From 2015 to 2021, 64 patients and a total of 90 lesions were irradiated. Treatment was well tolerated, with no G 3–4 toxicities. No grade ≥3 toxicities were registered and the coprimary endpoint of the study was met. Median follow-up was 19.4 months (range 2.6–73.1). Conclusions: The co-primary endpoint of this phase II trial was met, showing excellent tolerability of SBRT for lung and liver oligometastatic in breast cancer patients. Until efficacy data will mature with longer follow-up, SBRT should be regarded as an opportunity for oligometastatic breast cancer patients.

1 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
ABAlessio Bruni
Alessio Bruni
VSVieri Scotti
Vieri Scotti
MZMaria Alessia Zerella
Maria Alessia Zerella
FBFederica Bertolini
Federica Bertolini
JIJessica Imbrescia
Jessica Imbrescia
PBPaolo Borghetti
Paolo Borghetti
Background: Extensive-stage small-cell lung cancer (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among Italian clinicians, in particular about the integration with radiation therapy (RT). Methods: In June 2023, 225 Italian cancer care professionals were invited to complete a 21-question web-based survey about ES-SCLC management through personal contacts and the Italian Association for Radiotherapy and Clinical Oncology (AIRO) network. Results: We received 90 responses; the majority were radiation oncologists (89%) with more than 10 years of experience (51%). The preferred management of ES-SCLC in patients with a good performance status was concomitant chemo-immunotherapy (84%). Almost all respondents recommended prophylactic cranial irradiation (PCI) (85%), taking into account age and thoracic response; PCI was performed mainly between the end of chemotherapy and before starting immunotherapy (37%), with a three-dimensional conformal technique (46%). Furthermore, 83% of respondents choose to deliver thoracic RT in the case of both an intrathoracic and extrathoracic response, with an RT schedule of 30 Gy/10 fractions. Stereotactic RT is increasingly being used in oligoprogressions. Conclusions: Our analysis showed the variability of real-world management of ES-SCLC. Future clinical trials and developments are needed to improve the multidisciplinary treatment of these patients.

19 May 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DFDavide Franceschini
Davide Franceschini
MTM.A. Teriaca
M.A. Teriaca
PMPietro Mancosu
Pietro Mancosu
ABA. Bertolini
A. Bertolini
LFL. Lo Faro
L. Lo Faro
MSM. Scorsetti
M. Scorsetti